Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.

The Cochrane database of systematic reviews·2025

Same author

Strategies for ectopic expression of specific genes to enhance CAR-T cell tumoricidal capacity: How far are we from the clinical practice?

Pharmacological research·2025

Same author

Tetrandrine potentiates immunotherapy efficacy in non-small cell lung cancer: Modern wisdom of traditional Chinese medicine.

Pharmacological research·2024

Same author

Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports.

Frontiers in immunology·2023

Same author

Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway.

Cell death & disease·2022

Same author

Development of a sensitive UPLC-MS/MS assay for domperidone and pharmacokinetics of domperidone tablet formulations in fasting and fed Chinese healthy subjects .

International journal of clinical pharmacology and therapeutics·2020

Search research articles

Related Experiment Video

Updated: Aug 22, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Breaking boundaries: Current progress of anticancer NK cell-based drug development.

Shuhang Wang¹, Kun Chen², Yale Jiang¹

¹Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Drug Discovery Today

|November 12, 2022

Summary

Natural killer (NK) cell therapy offers a promising cancer treatment. Engineered NK cells can act as universal drugs, targeting various cancers effectively and overcoming limitations of traditional therapies.

Keywords:

NK cell therapy NK cells anticancer drugs drug design immunotherapy

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Related Experiment Videos

Last Updated: Aug 22, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Natural killer (NK) cells are innate immune cells that act as first-line responders against cancer and virus-infected cells.
NK cells utilize germline-encoded receptors for target recognition and are safe for allogeneic use, making them suitable for off-the-shelf applications.

Purpose of the Study:

To summarize and discuss the design principles of current anticancer NK cell therapies.
To highlight the potential of engineered NK cells as universal cancer therapeutics.

Main Methods:

Review of existing literature on NK cell therapy designs.
Analysis of NK cell receptor systems and antibody-guided targeting mechanisms.

Main Results:

NK cells offer an allogeneic, off-the-shelf advantage over autologous therapies.
Engineered NK cells can overcome HLA restrictions and target a broad range of cancer types, including rare cancers.

Conclusions:

NK cell therapy, particularly when engineered, presents a versatile and potent strategy for cancer treatment.
Further development of NK cell therapies promises broader patient benefit, especially for those with limited treatment options.